Japan Tobacco Inc.: EPS $0.669 vs $0.709 expected; revenue $6.39B vs $6.49B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.669 | 0.709 | −5.6% | 0.730 |
| Revenue (USD bn) | 6.390 | 6.490 | −1.5% | 6.080 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Q3 FY2026 | 0.6690 | 0.7090 | −5.6% | 6.39 | 6.49 | −1.5% |
| Jul 30, 2026 | Q2 FY2026 | 0.8130 | 0.6000 | +35.5% | 6.53 | 6.06 | +7.7% |
| May 8, 2026 | Q1 FY2026 | 0.6990 | 0.5890 | +18.7% | 5.82 | 5.66 | +2.8% |
| Feb 12, 2026 | Q4 FY2025 | −0.0056 | 0.2229 | — | 5.32 | 5.19 | +2.6% |
| Oct 30, 2025 | Q3 FY2025 | 0.7300 | 0.6280 | +16.2% | 6.08 | 6.09 | −0.2% |
| Jul 31, 2025 | Q2 FY2025 | 0.6320 | 0.5830 | +8.4% | 6.30 | 6.19 | +1.7% |
| May 7, 2025 | Q1 FY2025 | 0.5910 | 0.5480 | +7.8% | 5.51 | 5.31 | +3.8% |
| Feb 13, 2025 | Q4 FY2024 | 0.0751 | 0.1471 | −48.9% | 4.81 | 4.95 | −2.7% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
Japan Tobacco Inc. results: EPS $0.669 vs $0.709 expected; revenue $6.39B vs $6.49B. The results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 5.6%; revenue below the estimate by 1.5%. Figures are in USD as carried for this US-traded line; the company reports in JPY.
Revenue was up 5.0% from $6.08 billion a year earlier (Q3 FY2025). EPS was down 8.4% from $0.73 a year earlier. On its record, EPS topped analysts' estimates in 5 of 6 earlier comparable reports.
What the results mean
Japan Tobacco Inc.’s business rests on a tobacco portfolio spanning traditional products, heated tobacco and vapor products. This portfolio serves varied consumption preferences, while understanding operating performance requires examining product mix and demand across domestic and international markets.
Pharmaceuticals and processed foods diversify the company’s operations, with distinct drivers for each business. Pharmaceuticals involve research, development and the commercialization of treatments, while foods span frozen and prepared products and food ingredients. Interpreting the results therefore requires understanding how these activities contribute to profitability alongside tobacco.
What to watch on the earnings call: The earnings call merits attention for management’s discussion of demand for traditional tobacco, heated tobacco and vapor products, and how product and geographic mix affect margins. Spending on product development and marketing, along with the contribution of pharmaceuticals and processed foods to group profitability, also warrants attention.
For the full analysis of Japan Tobacco Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.